正在进行的疫苗和单克隆抗体HIV预防有效性试验和后续有效性试验设计的考虑因素
Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs
摘要:
正在进行4项候选疫苗或被动输注单克隆抗体预防HIV-1感染的随机安慰剂对照有效性试验(HVTN 702在南非男性和女性中; HVTN 705在撒哈拉以南非洲女性中; HVTN 703/HPTN 081在撒哈拉以南非洲女性中; HVTN 704/HPTN 085在美国,秘鲁、巴西和瑞士男性或与男性发生性关系的变性人)。后续疗效试验的最佳设计面临着几个挑战,包括:(1)如何解释可能成为试验设计或预防标准一部分的有效预防干预措施的不断演变的马赛克;(2)如何根据正在进行的每项试验的主要疗效结果和次要“保护相关性”结果来定义可行的和最佳的后续试验设计;以及(3)如果预期所有研究组中HIV-1的发病率都很低,以致标准试验设计具有陡峭的机会成本,则如何确定后续疗效试验的主要目的。在总结了正在进行的试验后,我讨论了统计学上的考虑因素,为后续疗效试验设计,一般和具体的每一个试验上面列出的。一个结论是,“保护相关性”分析的结果,确定不同的宿主免疫标志物和HIV-1病毒特征如何影响HIV-1风险和预防效果,对后续试验设计有重要影响。这种影响与单克隆抗体试验尤其相关,因为集中的试验前假设是血清中和的效力和覆盖范围构成HIV-1感染的替代终点。(see全文摘要的手稿)
英文摘要:
Four randomized placebo-controlled efficacy trials of a candidate vaccine or passively infused monoclonal antibody for prevention of HIV-1 infection are underway (HVTN 702 in South African men and women; HVTN 705 in sub-Saharan African women; HVTN 703/HPTN 081 in sub-Saharan African women; HVTN 704/HPTN 085 in U.S., Peruvian, Brazilian, and Swiss men or transgender persons who have sex with men). Several challenges are posed to the optimal design of the sequel efficacy trials, including: (1) how to account for the evolving mosaic of effective prevention interventions that may be part of the trial design or standard of prevention; (2) how to define viable and optimal sequel trial designs depending on the primary efficacy results and secondary 'correlates of protection' results of each of the ongoing trials; and (3) how to define the primary objective of sequel efficacy trials if HIV-1 incidence is expected to be very low in all study arms such that a standard trial design has a steep opportunity cost. After summarizing the ongoing trials, I discuss statistical science considerations for sequel efficacy trial designs, both generally and specifically to each trial listed above. One conclusion is that the results of 'correlates of protection' analyses, which ascertain how different host immunological markers and HIV-1 viral features impact HIV-1 risk and prevention efficacy, have an important influence on sequel trial design. This influence is especially relevant for the monoclonal antibody trials because of the focused pre-trial hypothesis that potency and coverage of serum neutralization constitutes a surrogate endpoint for HIV-1 infection... (see manuscript for the full abstract)
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。